Capecitabina Adverse Effects

Introduction to Adverse Effects

• The American Society of Clinical Oncology notes that the hand-foot syndrome is the most characteristic and frequent adverse effect of capecitabina, affecting up to 73% of patients, with 11% experiencing grade 3 events, which may require dose modifications or treatment interruptions 1

Hematologic Effects

• The National Comprehensive Cancer Network guidelines state that thrombocytopenia is especially common when capecitabina is combined with other agents 2

Toxicity in Combination Regimens

• The American Society of Clinical Oncology reports a higher incidence of hand-foot syndrome when capecitabina is combined with docetaxel (25.2% vs 1.3% with gemcitabine/docetaxel) 2, 3
• The National Comprehensive Cancer Network guidelines note a higher incidence of nausea/vomiting (8% vs 3.4%) and mucositis (4.4% vs 1.3%) when capecitabina is combined with docetaxel compared to gemcitabine/docetaxel 2, 3
• The Journal of the National Comprehensive Cancer Network reports a higher incidence of diarrhea when capecitabina is combined with other agents 4

Special Populations and Safety Considerations

• The American Society of Clinical Oncology states that patients over 65 years old have a higher risk of severe toxicity (34% grade 3 or higher toxicity), including treatment-related deaths 1, 5
• The National Comprehensive Cancer Network guidelines recommend that patients with renal insufficiency require dose adjustment since elimination is primarily renal 6

Management of Adverse Effects

• The National Comprehensive Cancer Network guidelines suggest that for toxicity grade 1, treatment should be continued with close monitoring 4

Capecitabine Management and Side Effects

Gastrointestinal Effects

• For mild diarrhea, the European Society of Medical Oncology recommends loperamide 4 mg four times daily 7
• For persistent diarrhea (>1 week), treatment as grade 2 diarrhea is recommended, according to the Gut journal 7
• For severe diarrhea, loperamide every 2 hours, and if no improvement after 24-48 hours, consider octreotide 100 μg three times daily, as suggested by the Gut journal 7
• For grade 3-4 diarrhea with neutropenia, fever, reduced oral intake, or other concerning symptoms, immediate hospitalization may be required, as stated in the Gut journal 7
• Capecitabine/5FU-induced enterocolitis is a rare but potentially serious complication that should be considered in patients with severe symptoms, according to the Gut journal 7
• Patients with partial or complete DPD deficiency (3-5% of population) may experience potentially life-threatening toxicity, as reported in the Gut journal 7

Nausea and Vomiting

• For moderate emetogenic chemotherapy regimens, the Multinational Association of Supportive Care in Cancer recommends 5-HT-receptor antagonist (preferably palonosetron) + dexamethasone 8 mg on day 1, followed by dexamethasone 8 mg on days 2-3 8

Capecitabine Therapy Management

Adverse Effects and Management

• Diarrhea is a common side effect, particularly when capecitabine is combined with other agents, as reported by the National Comprehensive Cancer Network 9
• The combination of capecitabine with neratinib results in a high incidence of diarrhea, with 83% of patients experiencing any grade of diarrhea and 24% experiencing grade 3/4 diarrhea, according to the National Comprehensive Cancer Network 10

Combination Therapy Considerations

• The National Comprehensive Cancer Network reports that the combination of capecitabine with neratinib leads to a significant incidence of grade 3 diarrhea, occurring in 29% of patients in combination trials 10

Adverse Effects and Management of the Capecitabine + Oxaliplatin (CapeOX) Regimen

Hand‑Foot Syndrome (Capecitabine)

• The NCCN guidelines state that capecitabine‑containing regimens produce a higher incidence of hand‑foot syndrome than bolus or infusional 5‑FU/leucovorin regimens. 11
• Development of capecitabine‑related hand‑foot skin reactions correlates with improved overall survival (median 75.8 months vs 41.0 months; hazard ratio 0.56). 11
• NCCN recommends assessing patients at each visit for early signs of hand‑foot syndrome and reducing the capecitabine dose promptly when toxicity appears. 11
• Patient education per NCCN: patients should stop capecitabine immediately if grade 2 hand‑foot syndrome (painful erythema affecting daily activities) develops. 11

Hematologic Toxicity (CapeOX vs. FOLFOX)

• NCCN data show that CapeOX causes markedly less myelosuppression than FOLFOX, with grade 3‑4 neutropenia in only 7 % of patients versus 41 % with FOLFOX. 11
• Annals of Oncology confirms the same pattern of reduced neutropenia for CapeOX compared with FOLFOX. 12

Renal Considerations

• NCCN advises dose modification of capecitabine for patients with diminished creatinine clearance because reduced renal function leads to drug accumulation and heightened toxicity risk. 11

Neuropathy (Oxaliplatin)

• NCCN identifies peripheral sensory neuropathy as the most significant dose‑limiting toxicity of oxaliplatin. 11
• Annals of Oncology reports grade 3 sensory neuropathy in 12 % of patients receiving FOLFOX and 8 % of those receiving FLOX regimens. 12
• NCCN recommends discontinuing oxaliplatin after 3–4 months of therapy (or sooner if neurotoxicity is unacceptable) while continuing capecitabine until disease progression. 11
• NCCN advises that oxaliplatin should not be re‑administered until near‑total resolution of any neurotoxicity that has occurred. 11
• NCCN does not routinely recommend calcium/magnesium infusions for prevention of oxaliplatin‑induced neurotoxicity, citing insufficient evidence. 11

Dose Modification and Monitoring Recommendations

• NCCN recommends a reduced starting dose of capecitabine (1,000 mg/m² twice daily) for North American patients because they experience a higher incidence of adverse events at standard doses used elsewhere (1,250 mg/m²). 11
• NCCN guidance: patients should immediately stop capecitabine for grade 2 diarrhea (4–6 stools/day), grade 2 nausea (significant reduction in food intake), grade 2 vomiting (2–5 episodes/24 h), grade 2 stomatitis (painful ulcers but able to eat), or fever ≥100.5 °F. 11

Comparative Toxicity Profile (CapeOX vs. FOLFOX)

• Combined NCCN and Annals of Oncology data indicate that CapeOX is associated with:
  
  • Less myelosuppression (grade 3‑4 neutropenia 7 % vs 41 % with FOLFOX). [11][12]
  • Less alopecia compared with FOLFOX. 11
  • Higher incidence of hand‑foot syndrome (≈31 % with CapeOX vs lower rates with FOLFOX). 11
  • Similar neurotoxicity (grade 3 sensory neuropathy 12 % with FOLFOX vs 8 % with FLOX). 12
  • More vomiting with CapeOX. 11
  • Comparable diarrhea rates between regimens. 11